Search Results - "de With, Mirjam"

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD by de With, Mirjam, van Doorn, Leni, Maasland, Demi C., Mulder, Tessa A.M., Oomen-de Hoop, Esther, Mostert, Bianca, Homs, Marjolein Y.V., El Bouazzaoui, Samira, Mathijssen, Ron H.J., van Schaik, Ron H.N., Bins, Sander

“…Occurrence of hand-foot syndrome (HFS) during capecitabine treatment often results in treatment interruptions (26 %) or treatment discontinuation (17 %), and…”
Get full text

The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer by Belderbos, Bodine P. S., de With, Mirjam, Singh, Rajbir K., Agema, Bram C., El Bouazzaoui, Samira, Oomen-de Hoop, Esther, de Wit, Ronald, van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander

“…Purpose Cabazitaxel, used in patients with metastatic castration-resistant prostate cancer (mCRPC), is associated with adverse events which may require dose…”
Get full text

Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma by Goey, Andrew Kl, With, Mirjam de, Agema, Bram C, Hoop, Esther Oomen-De, Singh, Rajbir K, van der Veldt, Astrid Am, Mathijssen, Ron Hj, van Schaik, Ron Hn, Bins, Sander

“…The pharmacokinetics and pharmacodynamics of vemurafenib are characterized by a wide interpatient variability. Since multiple polymorphic enzymes and drug…”
Get full text

CYP3A4∗22 Genotyping in Clinical Practice: Ready for Implementation? by Mulder, Tessa A. M., van Eerden, Ruben A. G., de With, Mirjam, Elens, Laure, Hesselink, Dennis A., Matic, Maja, Bins, Sander, Mathijssen, Ron H. J., van Schaik, Ron H. N.

“…Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the liver, responsible for the oxidative metabolism of ∼50% of clinically…”
Get full text

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients by Agema, Bram C, Koolen, Stijn L W, With, Mirjam de, Doorn, Nadia van, Heersche, Niels, Hoop, Esther Oomen-de, Visser, Sabine, Aerts, Joachim G J V, Bins, Sander, Schaik, Ron H N van, Mathijssen, Ron H J

“…Cisplatin is a chemotherapeutic agent widely used for multiple indications. Unfortunately, in a substantial set of patients treated with cisplatin,…”
Get full text

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients by Hulshof, Emma C., de With, Mirjam, Creemers, Geert-Jan, Guchelaar, Henk-Jan, Mathijssen, Ron HJ, Gelderblom, Hans, Deenen, Maarten J.

Get full text

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study by With, Mirjam, Knikman, Jonathan, Man, Femke M., Lunenburg, Carin A. T. C., Henricks, Linda M., Kuilenburg, André B. P., Maring, Jan G., Staveren, Maurice C., Vries, Niels, Rosing, Hilde, Beijnen, Jos H., Pluim, Dick, Modak, Anil, Imholz, Alex L. T., Schaik, Ron H. N., Schellens, Jan H. M., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk‐Jan, Mathijssen, Ron H. J., Swen, Jesse J., Meulendijks, Didier

“…In clinical practice, 25–30% of the patients treated with fluoropyrimidines experience severe fluoropyrimidine‐related toxicity. Extensively clinically…”
Get full text

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1 by de With, Mirjam, van Doorn, Leni, Kloet, Esmay, van Veggel, Anne, Matic, Maja, de Neijs, Micha J., Oomen - de Hoop, Esther, van Meerten, Esther, van Schaik, Ron H. N., Mathijssen, Ron H. J., Bins, Sander

“…Background and objective Side effects of irinotecan treatment can be dose limiting and may impair quality of life. In this study, we investigated the…”
Get full text

Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism? by Hulshof, Emma C., de With, Mirjam, Creemers, Geert-Jan, Guchelaar, Henk-Jan, Mathijssen, Ron HJ, Gelderblom, Hans, Deenen, Maarten J.

Get full text

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients by Hulshof, Emma C., de With, Mirjam, de Man, Femke M., Creemers, Geert-Jan, Deiman, Birgit A.L.M., Swen, Jesse J., Houterman, Saskia, Koolen, Stijn L.W., Bins, Sander, Thijs, Anna M.J., Laven, Marjan M.J., Hövels, Anke M., Luelmo, Saskia A.C., Houtsma, Danny, Shulman, Katerina, McLeod, Howard L., van Schaik, Ron H.N., Guchelaar, Henk-Jan, Mathijssen, Ron H.J., Gelderblom, Hans, Deenen, Maarten J.

“…To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan. In this prospective, multicentre,…”
Get full text

Response to “Plasma Uracil as a DPD Phenotyping Test: Pre‐analytical Handling Matters” by With, Mirjam, Knikman, Jonathan, Schellens, Jan H. M., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk‐Jan, Mathijssen, Ron H. J., Swen, Jesse J., Meulendijks, Didier

Get full text

Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer by Heersche, Niels, Veerman, G.D. Marijn, de With, Mirjam, Bins, Sander, Assaraf, Yehuda G., Dingemans, Anne-Marie C., van Schaik, Ron H.N., Mathijssen, Ron H.J., Jansman, Frank G.A.

“…Small-molecule kinase inhibitors (SMKIs) represent the cornerstone in the treatment of non-small cell lung cancer (NSCLC) patients harboring genetic driver…”
Get full text

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy by Mulder, Tessa A M, de With, Mirjam, Del Re, Marzia, Danesi, Romano, Mathijssen, Ron H J, van Schaik, Ron H N

“…Tamoxifen is a major option for adjuvant endocrine treatment in estrogen receptor (ER) positive breast cancer patients. The conversion of the prodrug tamoxifen…”
Get full text

Safety and pharmacokinetic analysis of UGT1A1 genotype-guided dosing of irinotecan by Hulshof, Emma C., de With, Mirjam, de Man, Femke M., Creemers, Geert-Jan, Deiman, Birgit ALM, Swen, Jesse J., Houterman, Saskia, Koolen, Stijn L.W., Laven, Marjan, Luelmo, Saskia, van Schaik, Ron H.N., Guchelaar, Henk-jan, Mathijssen, Ron H.J., Gelderblom, Hans, Deenen, Maarten J.

“…Abstract only 3574 Background: Irinotecan is commonly used in the treatment of advanced colorectal and pancreatic cancer. The polymorphisms UGT1A1*28 (7 TA…”
Get full text

Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study by Man, Femke M., Hussaarts, Koen G.A.M., With, Mirjam, Oomen‐de Hoop, Esther, Bruijn, Peter, Halteren, Henk K., Burg‐de Graauw, Nicole C.H.P., Eskens, Ferry A.L.M., Gelder, Teun, Leeuwen, Roelof W.F., Mathijssen, Ron H.J.

“…Regorafenib exposure could potentially be influenced by an interaction with acid‐reducing drugs. In this crossover trial, patients were randomized into two…”
Get full text

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy by de With, Mirjam, Hurkmans, Daan P, Oomen-de Hoop, Esther, Lalouti, Ayoub, Bins, Sander, El Bouazzaoui, Samira, van Brakel, Mandy, Debets, Reno, Aerts, Joachim G J V, van Schaik, Ron H N, Mathijssen, Ron H J, van der Veldt, Astrid A M

“…A substantial number of melanoma patients do not benefit from therapy with anti-PD-1. Therefore, we investigated the predictive value of single nucleotide…”
Get full text